Intravenous Iron in Perioperative Anemia

You know, in the OR, you are constantly surrounded by monitors, right? Beeping, flashing, and giving you that second-by-second data.

Right.

The usual symphony.

Exactly.

But sometimes the biggest threat to your patient isn't actually on a screen.

Sometimes it's a tool you aren't using just because of some outdated warning label stuck in your head.

Yeah, which perfectly explains why, despite all this massive evidence supporting intravenous iron for surgical anemia, almost nobody is actually using it.

I mean, look at France, right?

Okay, what's happening in France?

Up to 30% of major surgery patients are eligible, but only about 0.5% actually get it.

We're basically letting historical ghosts dictate modern practice.

It's wild.

So today's discussion of a highly relevant 2026 article from the British Journal of Anesthesia targets this exact problem, the NADA consensus recommendations.

Right.

Highly relevant for anesthesiologists.

Yeah.

We really want to separate those historical fears from modern clinical facts so you can confidently integrate IV iron into your perioperative practice.

Because the obvious roadblock here is, well, it's that lingering fear of severe hypersensitivity.

Right, the dreaded anaphylaxis.

Exactly.

But the issue is that true IgE-mediated anaphylaxis, it's exceedingly rare with modern non-dextrin iron formulations.

What clinicians are usually seeing are non-IgE-mediated fishbane reactions.

One of the most important distinctions in these recommendations is between true anaphylaxis and a more common, transient, fishbane-type infusion reaction.

Both can initially appear concerning, but their underlying mechanisms and clinical implications are very different.

Understanding that difference is essential, because it influences how we respond to a reaction and whether IV iron can be safely continued.

You know, in the OR, you are constantly surrounded by monitors, right? Beeping, flashing, and giving you that second-by-second data.

Right.

The usual symphony.

Exactly.

But sometimes the biggest threat to your patient isn't actually on a screen.

Sometimes it's a tool you aren't using just because of some outdated warning label stuck in your head.

Yeah, which perfectly explains why, despite all this massive evidence supporting intravenous iron for surgical anemia, almost nobody is actually using it.

I mean, look at France, right?

Okay, what's happening in France?

Up to 30% of major surgery patients are eligible, but only about 0.5% actually get it.

We're basically letting historical ghosts dictate modern practice.

It's wild.

So today's discussion of a highly relevant 2026 article from the British Journal of Anesthesia targets this exact problem, the NADA consensus recommendations.

Right.

Highly relevant for anesthesiologists.

Yeah.

We really want to separate those historical fears from modern clinical facts so you can confidently integrate IV iron into your perioperative practice.

Because the obvious roadblock here is, well, it's that lingering fear of severe hypersensitivity.

Right, the dreaded anaphylaxis.

Exactly.

But the issue is that true IgE-mediated anaphylaxis, it's exceedingly rare with modern non-dextrin iron formulations.

What clinicians are usually seeing are non-IgE-mediated fishbane reactions.

One of the most important distinctions in these recommendations is between true anaphylaxis and a more common, transient, fishbane-type infusion reaction.

Both can initially appear concerning, but their underlying mechanisms and clinical implications are very different.

Understanding that difference is essential, because it influences how we respond to a reaction and whether IV iron can be safely continued.